As of 2026-03-16, the EV/EBITDA ratio of Protagonist Therapeutics Inc (PTGX) is -36.00. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PTGX's latest enterprise value is 5,645.96 mil USD. PTGX's TTM EBITDA according to its financial statements is -156.82 mil USD. Dividing these 2 quantities gives us the above PTGX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 14.5x | 14.1x |
| Forward P/E multiples | 18.4x - 22.2x | 20.5x |
| Fair Price | (44.10) - (34.22) | (41.34) |
| Upside | -147.7% - -137.0% | -144.8% |
| Date | EV/EBITDA |
| 2026-03-13 | -36.00 |
| 2026-03-12 | -37.22 |
| 2026-03-11 | -37.65 |
| 2026-03-10 | -37.87 |
| 2026-03-09 | -37.72 |
| 2026-03-06 | -35.90 |
| 2026-03-05 | -35.62 |
| 2026-03-04 | -36.99 |
| 2026-03-03 | -35.58 |
| 2026-03-02 | -36.75 |
| 2026-02-27 | -35.89 |
| 2026-02-26 | -34.42 |
| 2026-02-25 | -33.91 |
| 2026-02-24 | -34.02 |
| 2026-02-23 | -33.70 |
| 2026-02-20 | -32.18 |
| 2026-02-19 | -32.31 |
| 2026-02-18 | -32.27 |
| 2026-02-17 | -32.06 |
| 2026-02-13 | -31.67 |
| 2026-02-12 | -31.84 |
| 2026-02-11 | -32.47 |
| 2026-02-10 | -32.62 |
| 2026-02-09 | -32.40 |
| 2026-02-06 | -32.87 |
| 2026-02-05 | -31.34 |
| 2026-02-04 | -32.39 |
| 2026-02-03 | -33.30 |
| 2026-02-02 | -32.29 |
| 2026-01-30 | -31.79 |
| 2026-01-29 | -30.97 |
| 2026-01-28 | -31.78 |
| 2026-01-27 | -32.30 |
| 2026-01-26 | -31.99 |
| 2026-01-23 | -32.31 |
| 2026-01-22 | -32.98 |
| 2026-01-21 | -32.63 |
| 2026-01-20 | -32.44 |
| 2026-01-16 | -31.87 |
| 2026-01-15 | -32.97 |
| 2026-01-14 | -33.16 |
| 2026-01-13 | -31.62 |
| 2026-01-12 | -31.17 |
| 2026-01-09 | -31.16 |
| 2026-01-08 | -31.15 |
| 2026-01-07 | -32.01 |
| 2026-01-06 | -31.98 |
| 2026-01-05 | -32.74 |
| 2026-01-02 | -33.94 |
| 2025-12-31 | -34.00 |